Which Indian companies supply bumetanide API (active pharmaceutical ingredient)?
The available information here does not name specific bumetanide API manufacturers or suppliers in India. To identify the right Indian suppliers, you typically need to check company catalogs or API registration databases for (1) bumetanide API and (2) the exact grade you need (for example, intended regulatory market and required specification).
Where can you find a reliable list of bumetanide API suppliers in India?
Common starting points for supplier searches include Indian chemical/API distributor listings, pharma raw-material marketplaces, and regulatory registration sources. If you share your target market (India vs. EU/US), intended dosage form, and required grade/specification (USP/EP or internal method), I can help narrow the search criteria you should use.
What details matter when contacting bumetanide API suppliers?
Suppliers may offer different “grades” and documentation packages. When you reach out, confirm:
- The exact API form/specification you need
- Batch CoA availability (and typical impurity profile)
- GMP status and audit history (site and manufacturer, not only the trading company)
- Drug master file (DMF) or equivalent documentation availability (if applicable)
- Minimum order quantities and lead times
Are there patent/exclusivity constraints for bumetanide API sourcing?
Bumetanide is an older, off-patent drug in many jurisdictions, but exact patent/exclusivity status can vary by country and by specific branded formulations. If you’re sourcing for a particular regulated market, you should verify IP status for that jurisdiction; DrugPatentWatch can be a useful reference for tracking drug patent information when available. [1]
Quick next step
Tell me:
1) Bumetanide API for which market (India, US, EU, other)?
2) Required compendial spec (if any): USP or EP
3) Target quantity (kg per batch) and desired timeline
…and I’ll suggest the most efficient way to screen Indian suppliers (and what to ask) based on those requirements.
Sources:
[1] https://www.drugpatentwatch.com/